Clinical trial
Toripalimab With Sequential Intravesical Gemcitabine-Mitomycin C Versus Toripalimab Alone for the Treatment of BCG-Unresponsive/-Intolerant High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized, Multicenter, Phase 2 Study
NCT07189793 is registered in ClinicalTrials.gov with First Affiliated Hospital of Wenzhou Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Toripalimab With Sequential Intravesical Gemcitabine-Mitomycin C Versus Toripalimab Alone for the Treatment of BCG-Unresponsive/-Intolerant High-Risk Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized, Multicenter, Phase 2 Study
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- October 31, 2028
- Enrollment
- 106 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
carcinoma in situ of bladder, carcinoma, transitional cell, non-muscle-invasive bladder cancer, urinary bladder neoplasms